甲磺酸那法莫司他可阻断新型冠状病毒激活：新冠肺炎的新治疗选择。 - Suppr

Suppr

超能文献

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.

作者信息

Hoffmann Markus, Schroeder Simon, Kleine-Weber Hannah, Müller Marcel A, Drosten Christian, Pöhlmann Stefan

机构信息

Deutsches Primatenzentrum-Leibniz Institute for Primate Research, Göttingen, Germany.

Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany.

出版信息

Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00754-20.

DOI:10.1128/AAC.00754-20

PMID:32312781

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7269515/

Abstract

摘要

相似文献

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.甲磺酸那法莫司他可阻断新型冠状病毒激活：新冠肺炎的新治疗选择。

Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00754-20.

The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.抗凝剂萘莫司他在细胞融合检测系统中能强力抑制 SARS-CoV-2 S 蛋白介导的融合，并以细胞类型依赖的方式在体外抑制病毒感染。

Viruses. 2020 Jun 10;12(6):629. doi: 10.3390/v12060629.

Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.将黏液溶解型止咳药及跨膜丝氨酸蛋白酶2（TMPRSS2）蛋白酶抑制剂溴己新重新用于预防和治疗新型冠状病毒肺炎（SARS-CoV-2）感染。

Pharmacol Res. 2020 Jul;157:104837. doi: 10.1016/j.phrs.2020.104837. Epub 2020 Apr 22.

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。

Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach.靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的进入步骤：一种有前景的治疗方法。

Signal Transduct Target Ther. 2020 Jun 17;5(1):98. doi: 10.1038/s41392-020-0195-x.

The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.TMPRSS2 抑制剂那法莫司他可降低 COVID-19 小鼠模型中的 SARS-CoV-2 肺部感染。

mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3.

Should we try the antiinflammatory natural product, celastrol, for COVID-19?我们应该尝试将抗炎天然产物雷公藤红素用于治疗新冠肺炎吗？

Phytother Res. 2020 Jun;34(6):1189-1190. doi: 10.1002/ptr.6711. Epub 2020 Apr 29.

Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.联合抑制宿主进入因子 PIKfyve 激酶和 TMPRSS2 蛋白酶对 SARS-CoV-2 感染的协同阻断。

J Virol. 2021 Oct 13;95(21):e0097521. doi: 10.1128/JVI.00975-21. Epub 2021 Aug 18.

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.新型冠状病毒肺炎患者使用甲磺酸萘莫司他和法匹拉韦治疗的相关不良事件。

Crit Care. 2020 Aug 12;24(1):497. doi: 10.1186/s13054-020-03227-4.

Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.羟氯喹联合甲磺酸萘莫司他连续性血液透析滤过治疗重症 COVID-19 患者的临床疗效。

J Infect Chemother. 2020 Dec;26(12):1319-1323. doi: 10.1016/j.jiac.2020.08.001. Epub 2020 Aug 6.

引用本文的文献

Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan-Coronavirus Inhibitor.病毒进入过程中刺突蛋白引发的破坏：粉防己碱作为一种泛冠状病毒抑制剂

MedComm (2020). 2025 Aug 31;6(9):e70353. doi: 10.1002/mco2.70353. eCollection 2025 Sep.

Association and Interaction of Epstein-Barr Virus with SARS-CoV-2 Infection-A Review.爱泼斯坦-巴尔病毒与严重急性呼吸综合征冠状病毒2感染的关联及相互作用——综述

Viruses. 2025 Jun 26;17(7):903. doi: 10.3390/v17070903.

Synergistic activation of bat SARS-like coronaviruses spike protein by elastase and TMPRSS2.弹性蛋白酶和跨膜丝氨酸蛋白酶2对蝙蝠SARS样冠状病毒刺突蛋白的协同激活作用

Sci Rep. 2025 Jul 21;15(1):26469. doi: 10.1038/s41598-025-11600-y.

Overview of host-directed antiviral targets for future research and drug development.未来研究和药物开发的宿主导向抗病毒靶点概述。

Acta Pharm Sin B. 2025 Apr;15(4):1723-1751. doi: 10.1016/j.apsb.2025.03.011. Epub 2025 Mar 8.

Drug discovery and development targeting the life cycle of SARS-CoV-2.针对新型冠状病毒生命周期的药物发现与开发。

Fundam Res. 2021 Mar;1(2):151-165. doi: 10.1016/j.fmre.2021.01.013. Epub 2021 Feb 1.

Structural basis of TMPRSS11D specificity and autocleavage activation.TMPRSS11D特异性和自切割激活的结构基础。

Nat Commun. 2025 May 10;16(1):4351. doi: 10.1038/s41467-025-59677-3.

Papaverine Targets STAT Signaling: A Dual-Action Therapy Option Against SARS-CoV-2.罂粟碱靶向 STAT 信号通路：一种针对 SARS-CoV-2 的双重作用治疗选择。

J Med Virol. 2025 Apr;97(4):e70319. doi: 10.1002/jmv.70319.

From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants.从N-0385到N-0920：揭示一种对流行的SARS-CoV-2变体具有皮摩尔抗病毒效力的宿主导向蛋白酶抑制剂。

J Med Chem. 2025 Apr 10;68(7):7119-7136. doi: 10.1021/acs.jmedchem.4c02468. Epub 2025 Mar 31.

The Ability of Combined Flavonol and Trihydroxyorganic Acid to Suppress SARS-CoV-2 Reproduction.黄酮醇与三羟基有机酸联合抑制新型冠状病毒复制的能力

Viruses. 2024 Dec 30;17(1):37. doi: 10.3390/v17010037.

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.一种口服可用的Mpro/TMPRSS2双特异性抑制剂，在体内具有强大的抗冠状病毒功效。

Res Sq. 2024 Nov 21:rs.3.rs-5454588. doi: 10.21203/rs.3.rs-5454588/v1.

本文引用的文献

Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。

Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.

TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection.TMPRSS2 促进冠状病毒感染后小鼠模型呼吸道中的病毒传播和免疫病理。

J Virol. 2019 Mar 5;93(6). doi: 10.1128/JVI.01815-18. Print 2019 Mar 15.

Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.使用基于分裂蛋白的细胞-细胞融合试验鉴定那法莫司他为中东呼吸综合征冠状病毒S蛋白介导的膜融合的有效抑制剂。

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539. doi: 10.1128/AAC.01043-16. Print 2016 Nov.

Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.中东呼吸综合征冠状病毒通过跨膜丝氨酸蛋白酶 2（TMPRSS2）介导感染。

J Virol. 2013 Dec;87(23):12552-61. doi: 10.1128/JVI.01890-13. Epub 2013 Sep 11.

The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies.新兴的贝塔冠状病毒 EMC 的刺突蛋白使用新型冠状病毒受体进入细胞，可被 TMPRSS2 激活，并可被中和抗体靶向。

J Virol. 2013 May;87(10):5502-11. doi: 10.1128/JVI.00128-13. Epub 2013 Mar 6.

Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts.流感病毒和严重急性呼吸综合征冠状病毒激活蛋白酶 TMPRSS2 和 HAT 在人类呼吸道和胃肠道的多个部位表达。

PLoS One. 2012;7(4):e35876. doi: 10.1371/journal.pone.0035876. Epub 2012 Apr 30.

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response.证据表明 TMPRSS2 激活严重急性呼吸综合征冠状病毒刺突蛋白进行膜融合，并降低体液免疫应答对病毒的控制。

J Virol. 2011 May;85(9):4122-34. doi: 10.1128/JVI.02232-10. Epub 2011 Feb 16.

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry.一种跨膜丝氨酸蛋白酶与严重急性呼吸综合征冠状病毒受体相连，并激活病毒进入。

J Virol. 2011 Jan;85(2):873-82. doi: 10.1128/JVI.02062-10. Epub 2010 Nov 10.

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.高效激活严重急性呼吸综合征冠状病毒刺突蛋白需要跨膜蛋白酶 TMPRSS2。

J Virol. 2010 Dec;84(24):12658-64. doi: 10.1128/JVI.01542-10. Epub 2010 Oct 6.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验